07/01/2005 18:12 FAX 8177424214 JUL 0 1 2005 Paperwork Reduction Act of 1995, no persons are required to respond to tute for turn 1449APTO INFORMATION DISCLOSURE

Sheet

Complete If Known

STATEMENT BY APPLICANT

of

(use as many sheets as necessary)

8

Appreciant unumer	100-0,201
Filing Date	11/07/2001
First Named Inventor	Browning, Jeffrey
Group Art Unit	TBD
Examiner Name	TBD
Altorney Docket Number	B129119CP2DV2CO

		MENT8	U.S. PATENT DOCU				
	Pages, Cotumns, Unes, Where Relevant Passages or Relevant Figures Access	Date of Publication of Clad Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Kind Code ¹	U.S. Paten	Cha No.1	miner
		7/6/82	Gilbert et al.		4,338,3	Al	,
		7/19/88	Mitsuhashi et al.	49	4,758,5	- 73	
		4/18/289	Powell		4,922,6		
		7/18/89	Thuring (pl.		4,849,5	- A4	M
							一
	•						一
							_
						$\neg \neg$	\neg
							一寸
		•					一
				-		_	
		1				-	
\neg	· · · · · · · · · · · · · · · · · · ·						
\neg					· · · · ·		
		A 7				-	\dashv
\neg				-			-
\neg		+		- 		-	
\neg		 	· · · · · · · · · · · · · · · · · · ·				

				FORE	IGN PATENT DOCUMENT	<u></u>			
mender	Cito	H	Foreign Patent Doc	Kind Code b	Name of Patentee or Applicant of Clied Document	Date of Publication of Clied Document	Pages, Columns, Lines, Where Resevent Pagesges or Relevent	7.	
Appla.	No.1	Ottoos	Number	(# to10≃n)	7 4 parametria	MM-DD-YYYY	Players Adodte	<u> </u>	N 01 . 1 AS
TX	ÐI		EP 0 367.575			5/9/90		نــــــــــــــــــــــــــــــــــــــ	Diplip
7								7	1/0/~
·		1				 		1	1
		╎╌┤		- 		1		+-	t
		╀				1		1-	t
		├				 		+	1 .
								+-	Į.
								+-	ł
								_	1
									1

Exeminer Signature	Dete Considered	8/31/05	

*EXAMINER: typical if reference considered, whether or not citation is in combinations with MPEP 809. Draw line through citation if not in conformance and not considered. (include copy of this form with next communication to applicant.

Burdon Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual code. Any comments on the amount of time you are required to complete this form should be east to the Chief Information Officer, Petent and Tradement Office, Weshington, DC 20231. DO NOT SEND FRES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Petents, Washington, DC 20231.

¹ Unique citation designation number. See stached Kinds of U.S. Patent Documents. Senter Office that latered the document, by the two-tetter code (WIPO Standard ST.S). See stached Kinds of U.S. Patent Documents. Sentence of the reign of the Emperor must precede the earlial number of the potent document. Sind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. Applicant is to place a check mark here if English banguage Translation is attached.

JUL 0 1 2005

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) ď

Comp	late if Known
Application Number	10/040,281
Filing Date	11/07/2001
First Named Inventor	Browning, Jeffrey
Group Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	B129USCP2DV2CO

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the suther (in CAPITAL LETTERS), (the of the strice (when appropriate), the of the	T
Examiner Initials	Cite No.1	Barri (Douit, magazine, journal, serial, sympothem, calelog, cto.), data, page(s), volume-basus number(a), publisher, city and/or country where published.	73
14	C1	Y. Abe et al., "Expression of Membrane-Associated Lymphotoxin/Turnor Necrosis Factor-Beia on Human Lymphokine Killer Cells", Jpn. J. Canc. Res., 82, pp. 23-26. (1991).	
	C2	Y. Abe et al. "Studies of Membran-Associated and Souble (Secreted) Lymphotoxin in Human Lymphokino-Activated T-Killer Cells in Vitro", Lymphokine and Cytokine Research, Vol. 11, pp. 115-121, (1992).	
	C3	Abersold et al., "Internal Amino Acid Sequence Analysis of Proteins Separated by One- or Two-Dimensional Gel Electrophorasis After in situ Protease Digestion on Nitrocellulose", PNAS, Vol. 84, pp. 6970-6974, (1987).	
	C4	B. Aggarwal et al., "Primary Streamer of Human Lymphotoxin Derived from 1788 Lymphoblastoid Cell Line", J. Biol. Chem., Vol. 260, No. 4, pp. 2334-2344, (1985).	
	C 5	M. Akashi et al., 'Lymphotoxin: Stimulation and Regulation of Colony-Stimulating Factors in Fibroblasts", Blood, 74, No. 7, pp. 2383-2390, (1989).	
	Ce	W.F. Anderson, "Human Gene Therapy", Science, Vol. 256, pp. 808-813 (1992).	
	C 7	U. Anderson et al., "Charagerization of Individual Tumor Necroils Factor alpha- and beta-Producing Cells after Polyclonal T Cell Activation", J. of Immun. Meth., 123, pp. 233-240, (1989).	
	C8	J.S. Andrews et al., Characterization of the Receptor for Tumor Necrosis Pactor (TNF) and Lymphotoxin (LT) on Human T Lymphocytes*, J. Immun. Vol. 144, No. 7, pp. 2528-2591, (1990).	
	C9	Androlewicz et al., "Lymphotoxin is Expressed as a Heteromeric Complex with a Dikinet 33-kDa Glycoprotein on the Surface of an Activated Human T Cell Hybridoma", Journal of Biological Chemistry", 267, No. 4, pp. 2547-2547, (1992).	
,,	210	R. Armitage et al., "Molecular and Biological Characterization of a Murine Ligand for CD40", Nature. Vol. 357, pp. 80-82, (1992).	
N	211	K. Badeshoop et al. "TNF-alpha Gene Polymurphisms in Type 1 (Insulin-Dependent) Diabetes Mellitis", Diabetelogia, 32, 445-448, (1989).	

Examiner	Deta	w/	/
		V/ ,	<i> (</i>
Signature	Considered	1131	())
		<u> </u>	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Think will very depending upon the nee the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Pate

16:13 FAX 6177424214

PTC/SB/08B (10-96)
Approved for use through 10/31/69, 0MB 0651-0031
Patent and Tradement Office: U.S. DEPARTMENT OF COMMERCE
script of information unless it contains a yaird GMB control number.

Ina Peperwork Reduction Act of 1995, no persons are required to respond to a col Complete If Known Substitute for form 14498/PTO Application Number 10/040,281 INFORMATION DISCLOSURE Filling Date 11/07/2001 STATEMENT BY APPLICANT First Named Inventor Browning, Jeffrey Group Art Unit TBD (use as many sheets as necessary) **Examiner Name** TBD Sheet œ **Attamey Docket Number** 8 B129USCP2DV2CO

Examiner Initials	Cita No.1	Include name of the author (in CAPITAL LETTERS), tills of the erticle (when appropriate), tills of the item (book, magazine, journal, sental, symposium, catalog, etc.), date, paga(e), volume-lasue number(e), publisher, city and/or country where published.	τ³
M	C12	B. Beutler et al., "The History, Properties, and Biological Effects of Cachemin", Biochemistry, Vol. 27, No. 20, pp. 7575-7582, (1988).	
	C13	T. Bringman et al., "Monoclonal Antibodies to Human Tumor Necrosis Factors alpha and beta: Application for Affinity Purification, Immunoassays, and as Structural Probes", Hybridoma, 6, No. 5, pp. 489-507, (1987).	
	C14	J. Browning et al., "Studies on the Differing Effects of Tumor Necrosis Factor and Lymphotoxin on the Growth of Several Human Tumor Lines", J. Immun., Vol. 143, No. 6, pp. 1859-1867, (1989).	
	C15	J. Browning et al., "Lymphotoxin and an Associated 33-kDa Glycoprotein are Expressed on the Surface of an Activated Human T Cell Hybridoma", J. Immunol., Vol. 47, No. 4, pp. 1230-1237, (1991).	
	C16	D. Cavender et al., "Endothelial Cell Activation Induced by Tumor Necrosis Pactor and Lymphotoxin", Amer. J. Path., Vol. 134, No. 3, pp. 551-560, (1989).	
	C17	R. Cotran et al., "Budothelial Activation, its kole in Inflammatory and Immune Reactions", Endothelial Cell Biology, pp. 335-347 (1988).	
	C18	N. Damle et al., "Distinct Regulatory Effects of IL-4 and TNP-alpha during CD3-Dependent and CD3-Independent Initiation of Human T-Cell Activation", Lymph Res., Vol. 8, No. 2, pp. 85-97, (1989).	
	C18	M. Eck et al., "The Structure of Turnor Necrosis Pactor-alpha at 2.6A Rasolution, Implications for Receptor Binding", J. Biological Chemistry, Vol. 264, No. 29, pp. 17595-17605 (1989).	
	C20	M. Eck et al., "The Structure of Human Lymphotoxin (Tumor Necrosis Factor-beta) at 1.9-A Resolution", J. Biological Chemistry, Vol. 257, No. 4, pp. 2119-2122, (1992).	
	C21	T. Farrah et al., "Emerging Cytokine Family", Nature, Vol. 358, p. 26, (1992).	
1.	222	G. Fuh eval., "Rational Design of Potent Antagonists to the Human Growth Hormone Receptor", Science, Vol. 256, pp. 1677-1680, (1992).	
W			

Examiner Signature	Date	8/3:1/5
California	Considered	0/0//

"EXAMENER: suitable reference considered, whisther or not ottation is in conformance with MPEP 608. Draw line strough chatton if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is extinated to take 2.0 hours to complete. Thre will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Tradement Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}Unique challon designation number. **Applicant to to place a check mark here if English language Translation is strached.

13 FAX B177424214

Sheet

JUL O 1 2005

PTO/BB/888 (10-86)
Approved for use through 10/31/89. OMB 0551-0031
Patent and Tradement Office: U.S. DEPARTMENT OF COMMERCE
the Percentage Reduction Act of 1995, no persons are required to respond to a collection of information united 8 portains a valid CMB control number.

10/040,281

11/07/2001

TBD

Complete If Known **Application Number** INFORMATION DISCLOSURE Filing Data STATEMENT BY APPLICANT First Named Inventor Browning, Jeffrey Group Art Unit (use as many sheets as necessary)

8

of

Examiner Name TBD **Attorney Docket Number** B129USCP2DV2CO

Exeminer Initials	CRs No.1	include name of the author (in CAPITAL LETTERS), the of the article (when appropriate), the of the ham (book, magazine, journal, eorial, symposium, catalog, etc.), data, pagu(a), volume-base number(a), publisher, oly and/or country where published.	77
M	C23	D. Goeddel et al., "Turnor Necrosis Factors: Gene Structure and Blological Activities", Cold Spring Harbor Symposis on Quant. Biol., pp. 597-609, (1986).	
	C24	G.A. Granger et al., "Lymphocyte In Vitro Cytotoxicity: Mechanisms of Immune and Non-Immune Small Lymphocyte Mediated Target L Cell Destruction", Journ, of Immun., 101, No. 1, pp. 111-120, (1968).	T
	C25	P. Gray, "Molecular Characterization of Human Lymphotoxin", Lymphotones, Vol. 13, pp. 199-208, (1987).	Γ
	C26	P. Gray et al., "Cloning and Expression of cDNA for Human Lymphotoxin, A Lymphokine with Tumor Necrosis Activity", Nature, 312, pp. 721-724. (1984).	T
	C27	L. Green et al., "Cytotoxic Lymphokines Produced by Cloned Human Cytotoxic T Lymphocytes", J. of Immun., 135, No. 6, pp. 4034-4043, (1985).	
1	C28	L. Green at al., "Rapid Colorimetric Assay for Cell Viability: Application to the Quantitation of Cytotoxic and Growth Inhibitory Lymphokines", J. of Immun. Meth., 70, pp. 257-268, (1984).	
	C29	J. Hiserods et al., "Identification of Membrane-Associated Lymphotoxin (LT) on Mitogen-Activated Human Lymphocytes Using Heterologous Anti-LT Antisera in Vitro", Cell. Immun., 34, pp. 326-339, (1977).	
	239	N. Itoh et al "The Polypeptide Encoded by the cDNA for Human Cell Surface Amigen FAS can Mediate Apoptosis", Cell, Vol. 66, pp. 238-243, (1991).	
	c31	E. Jones et al., "Structure of Turnor Necrosis Factor", Nature, 338, pp. 225-228, (1989)	
	C32	A. Kasid et al., "Human Gene Transfer: Characterization of Human Tumor-Infiltrating Lymphocytes as Vehicles for Retroving-Mediated Gene Transfer in Man", Proc. Natl. Acad. Sci. USA, 87, pp. 473-477, (1990).	
	:33	M. Kinkhabwata et al., "A Novel Addition to the T Cell Repency", J. Exp. Med., Vol. 171, pp. 941-946, (1990),	

Examiner Signature	Date Considered	8/31/05

"EXAMINER: In the it reference considered, whether or not obston in in conformance with MPEP 609. Draw line through charten if not in conformance and not considered. Include cognitative form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be cent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SENG FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is estached.

07/01/2003 16:14 FAX 6177424214

ess type a plus sign (+) inside this box

PTC/8b/068 (10-86)
Approved by use through 16/31/89, OMB 0651-031
Petert and Tredemark Office: U.S. DEPARTMENT OF COMMERCE action of information unless it contains a visit OMB control number.

ork Reduction Act of 1996, no paraone are required to respond to a c Complete If Known Substitute for form 1449B/PTO Application Number 10/040,281 INFORMATION DISCLOSURE 11/07/2001 Filing Date STATEMENT BY APPLICANT First Named Inventor Browning, Jeffrey Group Art Unit TBD (use so many sheets as necessary) Examiner Name TBD of **Sheat** 8 Attorney Docket Number B129USCP2DV2CO

Examiner Initiate	25 No.	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), tille of the fam (book, magazine, journal, sortal, symposium, catalog, etc.), data, poge(s), volume-lesus number(s), publisher, city and/or country where published.	77
M	C34	M. Kriegler et al., "A Novel Perm of TNF/Cathectin is a Cell Surface Cytotoxic Transmembrane Protein: Ramifications for the Complex Physiology of TNF", Cell, Vol. 53/pp. 45-53, (1988).	
1.	C35	Liang et al "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin", Biochem. Biophys. Res. Comm., Vol. 137, No. 2, pp. 847-854, (1986).	
	C36	C. Liu et al "Identification, Isolation, and Characterization of a Novel Cytotoxin in Murine Cytolytic Lymphocytes", Cell. Vol. 51, pp. 393-403, (1987).	-
	237	C. Liu et al., "Identification and Characterization of a Membrane-Bound Cytotoxin of Murine Cytolytic Lymphocytes that is Related to Turnor Neurosis Factor/Cacheodin", Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 3286-3290, (1989).	
	C38	B. Luertig et al., "Evidence for the Existence of Two Porms of Membrane Tumor Necrosis Factor: An Integral Protein and a Molecule Attached to its Receptor", J. Immun. 143. pp. 4034-4038, (1989).	
	C39	S. Mallett et al., "A New Superfamily of Cell Surface Proteins Related to the Nerve Growth Factor Receptor", immunology Today, Vol. 12, No. 7, pp. 220-223, (1991).	
	:40	L.J. Old, "Tumor Necrosis Factor (TNF)", Science, Vol. 230, pp. 630-632, (1985).	
	:41	N. Paul et al "Lymphotoxip", Ann. Rev. Immunol., 6, pp. 407-438, (1988).	
	C42	N. Paul et al., "Lymphotoxin Activation by Human T-Cell Leukemia Virus Type I-Infected Cell Lines: Role NF-kB", J. Viral., Vol. 64, No. 11, pp. 5412-5419, (1990).	
	C43	D. Pennica et al., Human Tumor Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin", Nature. Vol. 312, pp. 724-729, (1984).	
M	C44	A. Peterson et al., "Monoclonal Antibody and Ligand Binding Sites of the T Cell Erythrocyte Receptor (CD2)", Nature, Vol. 329, pp. 842-846, (1987).	

Examiner Signature	//	72-		Date Considered	d	31	105	
EXAMINER: Info	ual of reference considerance copy of this form with	, whether or not citation in next communication to ac	is in conformance with MPEP 908. opticant.	Draw line through	chatio	n it not	n contomance	and not

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. This will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trisdemark Office, Westington, DC 20221.

OO NOT SEND FEES OR COMPLETED FORMS 10 THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20221.

Unique obston designation number.
 Applicant is to place a check mark here if English language Translation is attached.

ATY PT FOOD 16: 14 FAX 6177424214

0 1 3002

PTC/8B/08B (10-86)
Approved for use through 10/31/99. CMB 0651-0031
Peters and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no parsons are required to recoond to a collection of information unless & contains a valid CMB control number.

Complete if Known Substitute for form 1449B/PTO Application Number 10/040,281 INFORMATION DISCLOSURE Filing Date 11/07/2001 STATEMENT BY APPLICANT First Named Inventor Browning, Jeffrey Group Art Unit TBD Exeminer Name (use as many sheets as necessary) TBD af **Attorney Decket Number** Sheet 8 B129USCP2DV2CO

Cunadan	- I	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the suther (in CAPITAL LETTERS), tills of the article (when appropriate), tills of the	T
Examiner Initials	Cta No.	Rem (book, megazine. journel, sartat, symposium, catalog, etc.), dete, pege(s), volume-base number(s), publisher, oty and/or country where published.	172
M	c4 5	P. Pociot et al., "A Tumor Necrosis Factor beta Gens Polymorphism in Relation to Monokine Secretion and Insulin-Dependent Diabetes Mellinus", Scand. J. Immunol., 33, pp. 37-49, (1997).	
\prod	C46	G. Ranges et al., "Tumor Necrosis Factor-alpha as a Proliferative Signal for an 12-2 Dependent T Cell Line: Strict Species Specificity of Action". J. of Immun., Vol. 142, pp. 1203-7208, (1989).	
	C47	O. Ranges et al., "Tumor Necrosis Pactor alpha/Cachectin is a Growth Factor for Thymnocytes", J. Exp. Med., Vol. 167, pp. 1472-1478, (1988).	
	C48	O.D. Roodman et al., "Tumor Necrosis Factor-alpha and Hematopoletic Progenitors: Effects of Tumor Necrosis Factor on the Growth of Erythroid Progenitors CFU-B and BFU-B and Hematopoletic Cell Lines K562, HL60, and HEL Cells", Exp. Hematology, 15, pp. 928-935, (1987).	
	C49	S. Rosenberg et al., "Use of Tumor-Infiltrating Lymphocyter and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma: A Preliminary Report? New Eng. Jour. of Med., Vol. 319, pp. 1676-1680, (1988).	
1.	C 50	N. Ruddle, "Lymphosoxin Redux", immun. Today, 6, pp. 156-159, (1985).	
	C51	N. Ruddle et al., "Cytotoxicity Mediated by Solable Antigen and Lymphocytes in Delayed Hypersensitivity", J. Exp. Med., 128, pp. 1237-1279, (1968).	
	:52	N. Ruddle et al., "The Role of Lymphopxin in Inflammation", Prog. Allergy, Vol. 40, pp. 162-182. (1988).	
	C 53	K. Sastry et al., "HIV-1 tat Gene/Induces Tumor Necrosis Pactor-beta (Lymphotoxin) in a Human beta-Lymphophastoid Cell Line", J. Biol. Chem., Vol. 265, No. 3, pp. 20091-20093, (1990).	
	C54	T. Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor". Call, Vol. 61, pp. 361, 370, (1990).	
4	C 55	P. Scheurich et el "Immunoregulatory Activity of Recombinant Human Tumor Necrosis Factor (TNF) -alpha: Induction of TNF Receptors on Human T Cells and TNF-alpha-Mediated Enhancement of T Cell Responses", J. Immun., Vol. 138, pp. 1786-1790 (1987).	

Examiner Signature	X	7	Date Consid	lered 8/	31/05
	/				7

*EXAMPLER: Infinit if reference considered, whether or not cluttion is in conformance with MPEP 609. Driew line through clienton if not in conformance and not considered. If clude copy of this form with next communication to applicant.

Burden Hour Statement: This forth is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the smount of time you are required to complete this form should be sent to the Citad Information Officer, Palant and Tradement Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Palants. Washington. DC 20231.

^{*} Unique claifon designation number. * Applicant to lo place a sheek mark here if English language Translation is effected.

Plant Spe a plus eign (+) incide this box ->+

PTC/SB/088 (10-86)
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
officering of Information unless it contains a veiled OMB control number.

Substitute for form 14498/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 7 of 8

Сотр	lete if Known	
Application Number	10/040,281	_
Filing Date	11/07/2001	
First Named Inventor	Browning, Jeffrey	
Group Art Unit	TBD	
Examiner Name	TBD	
Attorney Docket Number	B129USCP2DV2CO	

Bosminer	Cita	include name of the author (in CAPITAL LIETTERS), the of the article (when appropriate), the of the	Т
initiata'	No.1	item (book, mogazine, journel, eerial, symposium, catalog, etc.), data. pape(a), volume-boue number(a), publisher, city and/or pountry where published.	r
M	C5 6	M. Shalaby et al., "The Involvement of Human Tumor Necrosis Factors-alpha and beta in the Mixed Lymphocyte Reaction", J. Immun., Vol. 141, pp. 499-503, (1988).	Γ
7	C57	M. Sigel et al., "Production of Antibodies by Inoculation into Lymph Nodes", Math. in Bnz., Vol. 93, pp. 3-12 (1983).	
	C58	C. Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins", Science, 248, pp. 1019-1023, (1990).	
	C59	D. Spriggs et al., "Tumor Necrosis Factor Expression in Human Epithelial Tumor Cell Lines", J. Clin. Inves., Vol. 81, pp. 455-460, (1988).	
	C6 0	J. Tavernier et al., "Conserved Residues of Tumor Necrosis Fector and Lymphotoxin Constitute the Framework of the Trimeric Structure", Ped. Eur. Biognetn. Soc. Letters. Vol. 257, No. 2, pp. 315-318, (1989).	
	261	H. Thomas et al, "Biological Approaches to Cancer Therapy", J. Int. Med. Res., 17, pp. 191-204 (1989).	
	C62	M. Turner et al., Human T Cells from Ausbimmune and Normal Individuals can Produce Turnor Necrosis Pactor*, Bur. J. immun., 17, pp. 1807-1914 (1987).	
	C63	E. Tschachler et al., "Human Retroylrology: Constitutive Expression of Lymphotoxin (Tumor Necrosis Factor beta) in HTLV-1-Infected Cell Lines", Raven Press, pp. 105-113, (1990).	
	C64	R. Watenabe-Pukunaga et al. Lymphoproliferation Disorder in Mice Explained by Defects in Fas Anugen that Mediates Apoptosis*, Nature, 356, pp. 314-317, (1992).	
	C65	C. Warn et al., "Mechanisms of Lymphocyte-Mediated Cymtoxicity", J. Immun., Vol. 126, pp. 1927-1933, (1981).	
1	C66	C. Ware et al., "Human T Cell Hybridomas Producing Cytotoxic Lymphoteines: Induction of Lymphotoxin Release and Killer Cell Activity by Anti-CD3 Monoclonal Antibody or Lectins and Phorbol Ester", Lympholene Res., Vol. 5, No. 4, pp. 313-324, (1986).	

Exeminar Signature	0	Date Considered	8/3/05	
Olfumine.) =	Considered	0/3/02	

Burden Hour Sistement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office. Washington, DC 20221, DO NOT SEND FEEB OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Adeletes's Commissionar for Patents. Weakington, DC 20221,

[&]quot;EXAMINER! Initial if reference considered, whether or not obtain is in conformance with MPEP 609. Draw line through citation if not in conformance and not correlated. Include copy of this form with next communication to applicant.

Unique triation designation number. * Applicant is to place a check mark here if English language Translation is attached.

ANT O 1 JOHN FA

yease type a prius stign (+) inside this box →

the Pepsiwork Reduction Act of 1935, no persons are required to response

PTC/SB/088 - (10-66)
Approved for use through 10/31/99, OMB 0631-0031
Peters and Tredement Office: U.S. DEPARTMENT OF COMMERCE
a policition of information unless it contains a yard CMB control number,

Complete if Known 10/040,281 11/07/2001 **Application Number** INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor Browning, Jeffrey Group Art Unk TBD (use as many sheets as necessary) **Examiner Name** TED 6 Sheet 8 8 **Attorney Docket Number** B129USCP2DV2CO

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Intibila	CRa No.1	include name of the author (in CAPITAL LETTERS), this of the ericle (when appropriate), this of the liter (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-base number(s), publisher, day analyz country where published.	Τ°
M	c67	C. Ware et al., "Regulation of the CTL Lytic Pathway by Tumor Metrosis Factor", Cellular Immunity and the Immunotherapy of Cancer", UCLA Symposia on Molecular and Cell Biology M.T. Lotze and O.J. Finn, Eds., Vol. 135, pp. 121-128, (Wiley-Liss Inc. New York) 1990.	
_].	C68	C. Ware et al., "Expressions of Surface Lymphotoxis and Tumor Necrosis Pactor on Activated T. B. and Namiral Killer Cells", J. Immunol., Vol. 149, No. 12, pp. 3881-3888, (1992).	
	C69	L. Wysocki, U. Sato, "Panning" for Cymphocytes: A Method for Cell Selection", Proc. Natl. Acad. Sci. USA, Vol. 75, pp. 2844-2848, (1978).	
人	57 q	H. Yamanaka et al., Mentity of Human B-Cell Line Cytotoxic Lymphokine with Tumor Necrosis Factor Type beta*, Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 1343-1347, (1989)	
V			
		·	
			T
-			
			-
		*	
	ш		+-

Exeminer Signature Data Considered \$\\\ 31\\ o 5

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not infoontonnance considered, injude copy of this form with next communication to applicant.

1 Unique citation-designation number. PApplicant is to place a check mark here if English language Translation is essented.

Burden Hour Statement: This form is estimated to take 3.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments of the emount of time you are required to complete this form should be sent to the Crisel Information Officer, Peterd and Trademerk Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/S8/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO 10/040,281 Application Number INFORMATION DISCLOSURE Filing Date November 7, 2001 STATEMENT BY APPLICANT First Named Inventor Jeffrey L. Browning Art Unit 1635 (Use as many sheets as necessary) Examiner Name Sean McGarry Sheet 1 5 Attorney Docket Number **BGN-B129CP2D2CN RCE** of

	U.S. PATENT DOCUMENTS							
Exam Initial		Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
Sh	Ā	A1	4,338,397	07-06-1982	Gilbert, et al.			
		A2	4,758,549	07-19-1988	Mitsuhashi, et al.			
	Γ	A3	4,822,605	04-18-1989	Powell			
<u></u>	X	A4	4,849,509	07-18-1989	Thurin, et al.			

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,			
Initials*	No.1		Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear			
N	B1	EP 0367575	05-09-1990	Sankyo Company				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. I Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
xaminer nitials			T2			
M	C1	Abe, Y., et al. "Expression of membrane-associated lymphotoxin/tumor necrosis factor-beta on human lymphokine-activated killer cells." Jpn J Cancer Res. 1991 Jan; 82(1):23-6.				
	C2	Abe, Y., et al. "Studies of membrane-associated and soluble (secreted) lymphotoxin in human lymphokine-activated T-killer cells in vitro." Lymphokine Cytokine Res. 1992 Apr, 11(2):115-21.				
	СЗ	Abersold, et al. "Internal amino acid sequence analysis of proteins separated by one- or two-dimensional gel electrophoresis after in situ protease digestion on nitrocellulose." PNAS. 1987; 84:6970-4.				
	C4	Aggarwal, B.B., et al. "Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line." J Biol Chem. 1985 Feb 25; 260(4):2334-44.				
	C5	Akashi, M., et al. "Lymphotoxin: stimulation and regulation of colony-stimulating factors in fibroblasts." Blood. 1989 Nov 15; 74(7):2383-90.				
	C6	Anderson, W.F. "Human gene therapy." Science. 1992 May 8; 256(5058):808-13.	Т			
	C7	Anderson, U., et al. "Characterization of individual tumor necrosis factor alpha- and beta- producing cells after polyclonal T cell activation." J. of Immun. Meth. 1989; 123:233-40.				
	C8	Andrews, J.S., et al. "Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes." J Immunol. 1990 Apr 1; 144(7):2582-91.				
N	C9	Androlewicz, M.J., et al. "Lymphotoxin is expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated human T cell hybridoma." J Biol Chem. 1992 Feb 5; 267(4):2542-7.				

Examiner Signature	Date Considered	8/31/05



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	estitute for form 1449A/B/P	то		Complete if Known		
				Application Number	10/040,281	
11	NFORMATIO	N DI	SCLOSURE	Filing Date	November 7, 2001	
S	STATEMENT BY APPLICANT			First Named Inventor	Jeffrey L. Browning	
				Art Unit	1635	
	(Use as many sheets as necessary)			Examiner Name	Sean McGarry	
Sheet	2	of	5	Attorney Docket Number	BGN-B129CP2D2CN RCE	

	-	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²					
7	C10	Armitage, R.J., et al. "Molecular and biological characterization of a murine ligand for CD40." Nature. 1992 May 7; 357(6373):80-2.						
	C11	Badenhoop, K., et al. "TNF-alpha gene polymorphisms in type 1 (insulin-dependent) diabetes mellitus." Diabetologia. 1989 Jul; 32(7):445-8.						
	C12	Beutler, B., et al. "The history, properties, and biological effects of cachectin." Biochemistry. 1988 Oct 4; 27(20):7575-82.						
	C13	Bringman, T.S., et al. "Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes." <i>Hybridoma</i> . 1987 Oct; 6(5):489-507.						
	C14	Browning, J.L., et al. "Studies on the differing effects of tumor necrosis factor and lymphotoxin on the growth of several human tumor lines." J Immunol. 1989 Sep 15; 143(6):1859-67.						
	C15	Browning, J.L., et al. "Lymphotoxin and an associated 33-kDa glycoprotein are expressed on the surface of an activated human T cell hybridoma." J Immunol. 1991 Aug 15; 147(4):1230-7.						
	C16	Cavender, D.E., et al. "Endothelial cell activation induced by tumor necrosis factor and lymphotoxin." Am J Pathol. 1989 Mar, 134(3):551-60.						
	C17 Cotran, R.S., et al. "Endothelial activation, its role in inflammatory and immune reaction Endothelial Cell Biology. 1988; 335-47.							
	Damle, N.K., et al. "Distinct regulatory effects of IL-4 and TNF-alpha during CD3-dependent and CD3-independent initiation of human T-cell activation." Lymphokine Res. 1989; 8(2):85-97.							
	C19	Eck, M.J., et al. "The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding." J Biol Chem. 1989 Oct 15; 264(29):17595-605.						
	C20	Eck, M.J., et al. "The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution." J Biol Chem. 1992 Feb 5; 267(4):2119-22.						
	C21	Farrah, T., et al. "Emerging cytokine family." Nature. 1992 Jul 2; 358(6381):26.						
	C22	Fuh, G., et al. "Rational design of potent antagonists to the human growth hormone receptor." Science. 1992 Jun 19; 256(5064):1677-80.						
	C23	Goeddel, D.V., et al. "Tumor necrosis factors: gene structure and biological activities." Cold Spring Harb Symp Quant Biol. 1986; 51:597-609.						
1	C24 Granger, G.A., et al. "Lymphocyte in vitro cytotoxicity: mechanisms of immune and non-immune small lymphocyte mediated target L cell destruction." J Immunol. 1968 Jul; 101(1):111-20.							
	C25	Gray, P.W. "Molecular characterization of human lymphotoxin." Lumphokines. 1987; 13:199-208.						
	C26	Gray, P.W., et al. "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity." Nature. 1984 Dec 20-1985 Jan 2; 312(5996):721-4.						
	C27 Green, L.M., et al. "Cytotoxic lymphokines produced by cloned human cytotoxic T lymphocytes. I. Cytotoxins produced by antigen-specific and natural killer-like CTL are dissimilar to classical lymphotoxins." J Immunol. 1985 Dec; 135(6):4034-43.							
M	C28	Green, L.M., et al. "Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines." J Immunol Methods. 1984 May 25; 70(2):257-68.						
Examiner Signature	examiner Date							



PTC/SB/08a/b (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known		
				Application Number	10/040,281	
IN	NFORMATIO	ON DISC	CLOSURE	Filing Date	November 7, 2001	
S	TATEMENT	BY AF	PPLICANT	First Named Inventor	Jeffrey L. Browning	
				Art Unit	1635	
	(Use as many sheets as necessary)			Examiner Name	Sean McGarry	
Sheet	eet 3 of 5 Attorney Docket Number BGN-B129CP2D2CN R0		BGN-B129CP2D2CN RCE			

	·····		NON PATENT LITERATURE DOCUMENTS							
Examiner Cite Initials No.1			Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
1	7	C29	Hiserodt, J.C., et al. "Identification of membrane-associated lymphotoxin (LT) on mitogen-activated human lymphocytes using heterologous anti-LT antisera in vitro." <i>Cell Immunol.</i> 1977 Dec; 34(2):326-39.							
		C30	30 Itoh, N., et al. "The polypeptide encoded by the cDNA for human cell surface antigen Fas ca mediate apoptosis." Cell. 1991 Jul 26; 66(2):233-43.							
		C31	Jones, E.Y., et al. "Structure of turnour necrosis factor." Nature. 1989 Mar 16; 338(6212): 225-8.							
٠	C32 Kasid, A., et al. "Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man." Proc Natl Acad Sci USA. 1990 Jan; 87(1):473-7.									
		C33	Kinkhabwala, M., et al. "A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells." J Exp Med. 1990 Mar 1; 171(3):941-6.							
:		C34	Kriegler, M., et al. "A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF." Cell. 1988 Apr 8; 53(1):45-53.							
	C35 Liang, C.M., et al. "Production and characterization of monoclonal antibodies against recombinant human tumor necrosis factor/cachectin." Biochem Biophys Res Commun. 19 Jun 13; 137(2):847-54.									
		C36	Liu, C.C., et al. "Identification, isolation, and characterization of a novel cytotoxin in murine cytolytic lymphocytes." Cell. 1987 Nov 6; 51(3):393-403.							
		C37	Liu, C.C., et al. "Identification and characterization of a membrane-bound cytotoxin of murine cytolytic lymphocytes that is related to tumor necrosis factor/cachectin." Proc Natl Acad Sci USA. 1989 May; 86(9):3286-90.							
		C38	Luettig, B., et al. "Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor." <i>J Immunol.</i> 1989 Dec 15; 143(12):4034-8.							
		C39	Mallett, S., et al. "A new superfamily of cell surface proteins related to the nerve growth factor receptor." Immunol Today. 1991 Jul; 12(7):220-3.							
		C40	Old, L.J. "Tumor necrosis factor (TNF)." Science. 1985 Nov 8; 230(4726):630-2.							
	$oxed{oxed}$	C41	Paul, N.L., et al. "Lymphotoxin." Annu Rev Immunol. 1988; 6:407-38.							
		C42	Paul, N.L., et al. "Lymphotoxin activation by human T-cell leukemia virus type I-infected cell lines: role for NF-kappa B." J Virol. 1990 Nov; 64(11):5412-9.							
		C43	Pennica, D., et al. "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin." Nature. 1984 Dec 20-1985 Jan 2; 312(5996):724-9.							
		C44								
		C45	Pociot, F., et al. "A tumour necrosis factor beta gene polymorphism in relation to monokine secretion and insulin-dependent diabetes mellitus." Scand J Immunol. 1991 Jan; 33(1):37-49.							
P	C46 Ranges, G.E., et al. "Tumor necrosis factor-alpha as a proliferative signal for an IL-2-dependent T cell line: strict species specificity of action." J Immunol. 1989 Feb 15; 142(4):1203-8.									
	niner ature		Date Considered 8/51/05							



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/B/P7	ro		Complete if Known		
		Application Number 10/040,281			10/040,281	
11	NFORMATION	V DI	SCLOSURE	Filing Date	November 7, 2001	
S	TATEMENT I	BY APPLICANT		First Named Inventor	Jeffrey L. Browning	
				Art Unit	1635	
	(Use as many sh	eets as	necessary)	Examiner Name	Sean McGarry	
Sheet	4	of	5	Attorney Docket Number BGN-B129CP2D2CN RCE		

		NON PATENT LITERATURE DOCUMENTS														
Examiner nitials	Cite No.1	.1 magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, ci and/or country where published.														
M	C47	Ranges, G.E., et al. "Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines." J Exp Med. 1988 Apr 1; 167(4):1472-8.	Γ													
1	C48	Roodman, G.D., et al. "Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells." Exp Hematol. 1987 Oct; 15(9):928-35.														
	C49	Rosenberg, S.A., et al. "Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report." N Engl J Med. 1988 Dec 22; 319(25):1676-80.														
	C50	Ruddle, N.H. "Lymphotoxin redux." Immun. Today. 1985; 6:156-9.														
	C51	Ruddle, N.H., et al. "Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. I. Characterization of the phenomenon." J Exp Med. 1968 Dec 1; 128(6): 1237-54.														
	C52	Ruddle, N.H., et al. "The role of lymphotoxin in inflammation." Prog Allergy. 1988; 40:162-82.														
	C53	Sastry, K.J., et al. "HIV-1 tat gene induces tumor necrosis factor-beta (lymphotoxin) in a human B-lymphoblastoid cell line." J Biol Chem. 1990 Nov 25; 265(33):20091-3.	Ι.													
	C54	Schall, T.J., et al. "Molecular cloning and expression of a receptor for human tumor necrosis factor." Cell. 1990 Apr 20; 61(2):361-70.														
 C55 Scheurich, P., et al. "Immunoregulatory activity of recombinant human tumor necrosis fall (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses." J Immunol. 1987 Mar 15; 138(6):1786-90. C56 Shalaby, M.R., et al. "The involvement of human tumor necrosis factors-alpha and -beta mixed lymphocyte reaction." J Immunol. 1988 Jul 15; 141(2):499-503. C57 Sigel, M.B., et al. "Production of antibodies by inoculation into lymph nodes." Methods 																
							C58	Enzymol. 1983; 93:3-12. Smith, C.A., et al. "A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins." Science. 1990 May 25; 248(4958):1019-23.								
							C59	Spriggs, D.R., et al. "Tumor necrosis factor expression in human epithelial tumor cell lines." J Clin Invest. 1988 Feb; 81(2):455-60.	T							
	C60	Tavernier, J., et al. "Conserved residues of tumour necrosis factor and lymphotoxin constitute the framework of the trimeric structure." FEBS Lett. 1989 Nov 6; 257(2):315-8.														
	C61	Thomas, H., et al. "Biological approaches to cancer therapy." J Int Med Res. 1989 May-Jun; 17(3):191-204.														
	C62	Turner, M., et al. "Human T cells from autoimmune and normal individuals can produce tumor necrosis factor." Eur J Immunol. 1987 Dec; 17(12):1807-14.	T													
1	C63	Tschachler, E., et al. "Human retrovirology: constitutive expression of lymphotoxin (tumor necrosis factor beta) in HTLV-I-infected cell lines:" Raven Press, 1990; pp. 105-13.	T													
1	C64	Watanable-Fukunaga, R., et al. "Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis." <i>Nature</i> . 1992 Mar 26; 356(6367):314-7.	T													
W	C65	Ware, C.F., et al. "Mechanisms of lymphocyte-mediated cytotoxicity. II. biochemical and serologic identification of a precursor lymphotoxin form (pre-LT) produced by MLC-sensitized human T lymphocytes in vitro." J Immunol. 1981 May; 126(5):1927-33.														
xaminer ignature		Date Considered 8/3//05														



PTC/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449A/B/PTO			Complete if Known		
		_		Application Number	10/040,281	
IN	IFORMATIO	ON DISC	CLOSURE	Filing Date	November 7, 2001	
S	TATEMENT	BY AF	PLICANT	First Named Inventor	Jeffrey L. Browning	
				Art Unit	1635	
	(Use as many sheets as necessary)			Examiner Name	Sean McGarry	
Sheet	neet 5 of 5 Attorney Docket Number BGN-B129CP2D2CN R		BGN-B129CP2D2CN RCE			

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²					
M	C66 Ware, C.F., et al. "Human T cell hybridomas producing cytotoxic lymphokines: lymphotoxin release and killer cell activity by anti-CD3 monoclonal antibody or phorbol ester." Lymphokine Res. 1986; 5(4):313-24.							
	C67	Ware, C.F., et al. "Regulation of the CTL lytic pathway by tumor necrosis factor." Cellular Immunity and the Immunotherapy of Cancer. UCLA Symposia on Molecular and Cell Biology, M.T. Lotze and O.J. Finn, Eds., 1990; 135:121-8 (Wiley-Liss Inc., New York).						
	C68	Ware, C.F., et al. "Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells." J Immunol. 1992 Dec 15; 149(12):3881-8.						
	C69	Wysocki, L.J., et al. "Panning" for lymphocytes: a method for cell selection." Proc Natl Acad Sci USA. 1978 Jun; 75(6):2844-8.						
4	C70	Yamanaka, H.I., et al. "Identity of human B-cell line cytotoxic lymphokine with tumor necrosis factor type beta." Proc Natl Acad Sci USA. 1989 Feb; 86(4):1343-7.						

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	Date Considered	0/3/1	າ ໌

^{&#}x27;Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.